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Abstract 
Lipid droplet formation and subsequent steatosis has been reported to contribute to hepatotoxicity and 
is an adverse effect of many pharmacological agents including the anti-epileptic valproic acid (VPA).  In 
this study, we have developed a simple model system Dictyostelium discoideum to investigate the 
effects of VPA and related compounds in lipid droplet formation. In mammalian hepatocytes, VPA 
increases lipid droplet accumulation over a 24 hour period giving rise to liver cell damage, and we show 
a similar effect in Dictyostelium following 30 minute VPA treatment.  Using 3H-labelled poly-unsaturated 
(arachidonic) or saturated (palmitic) fatty acids, we shown VPA treatment of Dictyostelium gives rise to 
an increased accumulation of both fatty acids in phosphatidylcholine, phosphatidylethanolamine and 
non-polar lipids in this time period, with a similar trend observed in Human hepatocytes (Huh7 cells) 
labelled with 3H-arachidonic acid.  In addition, pharmacological inhibition of β-oxidation in Dictyostelium 
phenocopies fatty acid accumulation, in agreement with data reported in mammalian systems.  Using 
Dictyostelium, we then screened a range of VPA-related compounds to identify compounds with high 
and low lipid-accumulation potential, and validated these activities for effects on lipid droplet formation 
using human hepatocytes. Structure-activity relationships for these VPA-related compounds suggest 
that lipid accumulation is independent of VPA-catalysed teratogenicity and inositol depletion. These 
results suggest that Dictyostelium may provide both a novel model system for the analysis of lipid 
droplet formation in human hepatocytes and a rapid method for identifying VPA-related compounds 
showing liver toxicology.   
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1. Introduction 
Valproic acid (VPA) was first identified as an antiepileptic in 1963 (Meunier et al. 1963) and since then it 
has become a commonly used treatment for epilepsy, bipolar disorder and migraine (Lagace et al. 
2005;Terbach and Williams 2009).  In trying to understand the therapeutic role of VPA, a range of 
cellular effects have been identified including inositol depletion (associated with bipolar disorder 
treatment (Eickholt et al. 2005;Shimshoni et al. 2007;Williams 2005;Williams et al. 2002)) and histone 
deacetylase (HDAC) inhibition (associated with teratogenicity (Gottlicher et al. 2001;Phiel et al. 2001)).  
In addition, VPA is associated with a range of adverse effects including hepatotoxicity, tremors, alopecia 
and drowsiness (Lagace et al. 2005). Hepatotoxicity is more severe in those patients on multiple 
prescriptions; however the related condition of non-alcoholic fatty liver disease or steatosis (abnormal 
lipid accumulation) is also frequent in patients taking VPA, alone or in combination with other agents 
(Luef et al. 2009;Verrotti et al. 2011a). Thus the analysis of hepatotoxicity and steatosis in relation to 
VPA treatment, and the development of model systems for this research are important priorities as they 
will enable the development of novel therapeutics with improved risk:benefit ratios. 
 
Within mammalian cells, fatty acids such as the polyunsaturated fatty acid arachidonic acid (AA) 
(Svennerholm 1968) may be incorporated into phospholipids directly or stored as non-polar lipids such 
as diacyl and triacylglycerols (DAG/TAGs) prior to reincorporation or metabolism. Release of the fatty 
acid from these phospholipids or other lipid classes occurs mainly through lipase-catalysed catabolism 
such as phospholipase A2 (PLA2)(Rapoport 2008). Once released, free (non-esterified) fatty acid species 
may then be re-incorporated or transported to the mitochondria to be metabolised by β-oxidation.  VPA 
treatment has been shown to act as a PLA2-like inhibitor (Bosetti et al. 2003;Rapoport and Bosetti 2002), 
reducing expression of defined isoforms of PLA2 (Chang et al. 2001) while also disrupting fatty acid β-
oxidation(Aires et al. 2011;Silva et al. 2008).  A range of in vitro mammalian models have been used to 
show VPA-induced hepatotoxicity and steatosis effects (Eadie et al. 1988)  with increased lipid droplet 
accumulation observed in hepatocytes (Fujimura et al. 2009)  and skeletal muscle (Melegh and 
Trombitas 1997). Whilst this VPA-catalysed effect is likely to cause liver damage to individuals 
undergoing treatment, it remains possible that these effects may be disassociated from the therapeutic 
mechanisms; thus a better understanding of compounds causing this effect is of interest in the design of 
novel therapeutics.   
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Structure activity relationship (SAR) studies have previously been employed to delineate the potential 
targets of VPA (Bialer et al. 2010;Eickholt et al. 2005;Eikel et al. 2006;Eyal et al. 2005;Shimshoni et al. 
2007). In this approach, the structural characteristics of VPA-related compounds can be used to isolate 
and characterise the molecular mechanism of individual effects which can then be used to differentiate 
between distinct mechanisms of action. SAR studies have been used to examine the teratogenic nature 
of VPA which is thought to be due to inhibition of histone deacetylase function (Eikel et al. 2006;Phiel et 
al. 2001;Spiegelstein et al. 2000).  Similarly, the inhibition of inositol phosphate signalling by VPA has 
also been examined in SAR studies in both Dictyostelium cells and mammalian neurons (Eickholt et al. 
2005;Shimshoni et al. 2007;Williams et al. 2002). These previous studies have clearly identified distinct 
structural characteristics of VPA-related compounds responsible for these effects and therefore are 
likely to have different mechanisms of action. It remains unclear if either of these effects is related to 
lipid accumulation, which is the aim of the current investigation. 
 
In this study, we have examined VPA-induced lipid accumulation in Dictyostelium discoideum.  We have 
previously used this model to characterise the effect of VPA in inositol trisphosphate (InsP3) (Eickholt et 
al. 2005;Shimshoni et al. 2007;Williams et al. 2002)and phospholipid (Chang et al. 2009;Xu et al. 2007) 
signalling, with subsequent translation in mammalian systems. Here we show that in Dictyostelium, 
pharmacologically-relevant concentrations of VPA acutely enhance the uptake of fluorescently-labelled 
and radio-labelled fatty acids (both poly-unsaturated fatty acid [3H]-AA and the saturated fatty acid [3H]-
PaA (palmitic acid)), and that the increase in fatty acid uptake occurs concurrently with a decrease in 
fatty acid release. Analysis of the cellular distribution of incorporated, radio-labelled fatty acids by 2-
dimensional TLC revealed that VPA-induced fatty acid accumulation increased the overall accumulation 
in all phospho- and non-polar lipids examined but did not alter the overall distribution within lipids, and 
an equivalent trend is shown using human hepatocytes (Huh7 cells) following [3H]-AA labelling. In 
Dictyostelium, a similar effect of lipid accumulation is shown by pharmacological inhibition of -
oxidation. Analysis of series of VPA-related compounds in Dictyostelium identified a broad range of 
activities, tightly defined by structure, and a selection of these compounds was then used in human 
hepatocytes (Huh7 cells) to show corresponding lipid accumulation. Finally, using a range of compounds 
with known teratogenic or inositol-depleting activity, we show the biological effect of VPA-induced fatty 
acid accumulation may be independent of inositol depletion and HDAC inhibition/teratogenicity 
indicating the potential for identifying VPA-based therapeutics with reduced hepatotoxic liability.  
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2. Materials & Methods 
2.1 Reagents 
3H arachidonic acid was purchased from Hartmann analytic (Germany); 3H palmitic acid was from Perkin 
Elmer (Cambridge, UK). VPA related compounds were provided by Heinz Nau, Sigma Aldrich UK, Alfa 
Aesar Ltd, ChemSampCo Ltd., TCI Europe, Avocado, ACC Corporation, Katwijk Chemie and VWR. 
 Dictyostelium media was supplied by Formedium (Norfolk, UK). Isoproyl-pentanoic acid (PIA), (2R)-
isopropyl-pentamamide (PID), 2,2,3,3-tertramethylcyclopropanecarboxylic acid (TMCA), 3-methyl-2-
isopropylbutanoic acid and 4-methylpentanoic acid were generously provided by Prof M. Bialer (The 
Hebrew University of Jerusalem, Israel).  All reagents were supplied by Sigma Aldrich (Poole, UK). 
 
2.2 Cells and development  
Dictyostelium cells were grown in axenic medium or on Sussman’s agar plates in association with 
Raoultella planticola(Drancourt et al. 2001). Dictyostelium cells were artificially developed by placing in 
phosphate buffer (16.5mM KH2PO4, 3.8mM K2HPO4) and pulsing with 25nM cAMP every 6 minutes for 
4 hours at 20oC.  Cell labeling was carried out by the addition of radio-labelled lipid to pulsing cells for a 
further 60 minutes (Boeckeler et al. 2006).   
 
The Huh7 human hepatocellular carcinoma cell line (Nakabayashi et al. 1982)  was a kind gift from Dr 
Steve Hood (GSK, Ware, UK). All cells were routinely cultured in 75 cm2 vented tissue culture flasks 
(Nunc, UK) using minimal essential medium with Earle's salts supplemented with 1% non-essential 
amino acids, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% foetal bovine 
serum. In order to maintain phenotypic consistency, Huh7 cells were only used for three weeks 
(approximately 5 passages) following recovery from liquid nitrogen.  For imaging analysis, 1 x 105 cells 
were seeded into 6 well plates containing sterile coverslips or 2.5 x 104 cells seeded into 24 well plates.  
Cells were allowed to adhere at 37°C for >2 hours prior to treatment as indicated in figure legends. 
 
2.3 Lipid droplet analysis 
Oil Red-O staining was performed on cells fixed overnight in 10% formalin (3.7% formaldehyde) in PBS 
before washing twice with 70% ethanol and water.  Cells were stained with 0.18% oil Red-O for 10 
minutes, washed with ethanol and water prior to hematoylin counterstain.  
 
2.4 Fatty acid uptake and release 
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For fatty acid uptake, Dictyostelium cells were pulsed with cAMP (as above) for 4 hours in shaking liquid 
culture at 2.5 x 106 cells/ml prior to the addition of 0.25µCi of 3H-labelled fatty acid added in 0.5% fatty 
acid free BSA at which point drugs were also added at the indicated concentrations. Samples were taken 
at indicated times (by removing about 7.5 x 105 cells for scintillation counting and 3 x 107 cells for TLC 
analysis and washing once in phosphate buffer).   
 
For fatty acid release experiments, cells were pulsed (as above) for 4 hours at 1.5 x 106 cells/ml.  Cells 
were then labelled by resuspending in phosphate buffer with 0.5% fatty acid free BSA and 0.25µCi of 3H-
labelled fatty acid for 1 hour.  Unincorporated 3H was removed by washing twice in phosphate buffer.  
Cells were finally resuspended in phosphate buffer/BSA at 5 x 106 cells/ml and 300µl samples (5%) 
removed at indicated time points.  Samples were briefly centrifuged to remove cells and 250µl of 
supernatant was removed for scintillation counting.   
 
C1-BODIPY-C12 labelling employed 4 hour pulsed cells, incubated with fluorescent fatty acid (Invitrogen) 
for 30 min in the presence or absence of VPA (0.5 mM) and images were recorded on an Olympus IX 71 
inverted fluorescence microscope with Retiga EXi Fast 1394 camera and analysed by ImagePro™ 
software. Data was obtained from three independent experiments (totalling 161 images each) for 
control and VPA treatment. 
 
1D TLC analysis was performed as previously described (Pawolleck and Williams 2009).  Briefly, lipids 
were extracted from cells with 2:1 chloroform: methanol, dried and separated using the TLC solvent 
40:15:13:12:7 chloroform:acetone:methanol:acetic acid:distilled water. 2D TLC analysis was performed 
on lipids extracted as previously described (Garbus et al. 1963).  Lipids were separated first in a basic 
solvent (chloroform: methanol: ammonium hydroxide, 65:25:4, v/v/v) followed, in the second 
dimension, by an acidic solvent (n-butanol: acetic acid: water, 90:20: 20, v/v/v).  Plates were sprayed 
with 0.2% (wt/vol) 8-anilino-4-naphthosulphonic acid (ANSA) in methanol prior to visualisation under UV 
fluorescence.  Quantification of spots was performed by phosphorimaging or scraping of spots and 
scintillation counting. 
 
2.5 Statistical analysis 
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Graphical and statistical analysis was carried out using Graphpad Prism software.  Error bars show +/- 
standard error of mean (SEM) and statistical significance was carried out using Student’s t test.  All data 
represent at least n ≥ 3. Fatty acid uptake and release data are expressed as a % cpm of control.    
 8 
3. Results 
3.1 VPA increases fatty acid accumulation 
To investigate the utility of using Dictyostelium to analyse lipid droplet formation following VPA-
treatment, we visualised VPA-induced fatty acid accumulation with a compound containing a 12 carbon 
fatty acid chain linked to a fluorescent head group (C1-BODIPY-C12)(von Lohneysen et al. 2003;Worsfold 
et al. 2004). Upon incubation of cells with C1-BODIPY-C12-labelled lipid, VPA (0.5 mM) caused a large 
increase in the intensity and a small but significant increase in diameter of fluorescent lipid droplets 
within cells compared to untreated cells (Fig. 1a, b). These changes were observed after only 30 minute 
treatment with VPA and are comparable to the lipid accumulation observed in hepatocytes after 24 
hours (Fujimura et al. 2009).  
 
To quantify this effect of increase lipid accumulation in Dictyostelium, we measured the uptake of 3H-AA 
fatty acid into cells over time, to show linear incorporation over a 30 min period (Fig. 2a). VPA caused a 
dose-dependent increase in 3H-AA fatty acid incorporation, with an EC50 of 47 µM (Fig. 2a insert).  This 
effect is not fatty acid specific since similar results were also seen using 3H-PaA, with an EC50 value of 
160 µM VPA (Fig. 2b and insert). For both fatty acids, increased uptake was significant following 30 min 
treatment (p<0.05). These results were confirmed following lipid extraction and 1D TLC separation with 
duplicate samples following 30 and 60 min VPA (0.5mM) treatment (Fig. 2 c-d).   
 
We also assessed the release of radio-label into medium from cells labelled with either 3H-AA or 3H-PaA.  
In both cases, the release of radio-label was linear over a 30 min period (Fig. 2e-f).  Inhibition of this 
release by VPA (0.5 mM) was acute and dose-dependent, with an IC50 of 89 µM and 163 µM for 3H-AA 
and 3H-PaA respectively (Fig. 2e-f inserts), with both 3H-AA and 3H-PaA labelled cells showing a 
significant reduction in 3H release after 30 min exposure (0.5mM) (p<0.05).  This provided a fast and 
easy assay for determining the deregulation of fatty acid accumulation by VPA in Dictyostelium. 
 
We then examined the specific phospholipid classes involved in increased fatty acid incorporation 
regulated by VPA. In these experiments, Dictyostelium cells were labelled for 60 min with 3H-AA or 3H-
PaA in the absence or presence of VPA (1 mM), and then lipids were extracted and separated by 2D TLC 
prior to quantification by scintillation counting.  Equal lipid loading was validated by UV visualisation of 
2D separated lipids (Fig. 3a and b). VPA treatment caused a strong and significant increase in 
incorporation of both 3H-AA and 3H-PaA into phosphatidylcholine (PC) and phosphatidylethanolamine 
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(PE) (Fig. 3c, d).  VPA did not alter the preference of phospholipid species retaining each fatty acid, 
suggesting the mechanism of action is not restricted to a specific class of lipid.  As well as phospholipid 
incorporation, TLC analysis revealed a significant increase in fatty acid accumulation in non-polar lipids 
(Fig. 3c, d) which correlates with the observed lipid droplet accumulation in Dictyostelium and 
hepatocytes.  Repeating the 3H-AA labelling experiments in a human hepatocytes cell line (Huh7), 
showed a similar trend to increased incorporation into phospholipids and non-polar lipids (Fig. 3e). 
 
3.2 Inhibition of -oxidation partially phenocopies VPA regulation of fatty turnover  
To investigate the mechanism of VPA-induced lipid accumulation, we assessed the role of inhibiting 
various lipid-turnover associated enzymes on 3H-AA in Dictyostelium using a pharmacological approach 
(Fig. 4a). Since VPA has been associated with a PLA2-inhibitory like effects  (Bosetti et al. 2003;Rapoport 
and Bosetti 2002), we first used a combination of PLA2 class-specific inhibitors (BEL [80 μM], a Ca
2+-
independent PLA2 inhibitor(Ackermann et al. 1995); MAFP [50 μM], an inhibitor of Ca
2+-dependent and 
Ca2+-independent cytosolic PLA2 (Balsinde and Dennis 1996;Lio et al. 1996); and BPB [20 μM], a general 
phospholipase A2 inhibitor (Mitchell et al. 1977)).  This PLA2-inhibitor cocktail gave the opposite effect to 
VPA showing reduced fatty acid accumulation (Fig. 4b).  Similarly, the reduction of diacylglycerol (DAG) 
acyltransferase activity, responsible for conversion of diacylglycerol to triacylglycerol using an acyl-CoA 
substrate (with the inhibitor xanthohumol,50 M), also inhibited fatty acid accumulation.  However, the 
use of 2-mercaptoacetate (2-MA; 15 mM) previously shown to inhibit long-chain acyl-CoA 
dehydrogenase in the -oxidation of fatty acids (Bauche et al. 1983), phenocopied the effect of VPA by 
causing an increase in fatty acid uptake (Fig. 4b). Combining VPA and 2-MA (Fig. 4c) gave rise to a 
significant increase in uptake (p= 0.04) above VPA-alone, and similar to that of 2-MA alone, suggesting 
that VPA may function in this effect by weakly inhibiting the -oxidation of fatty acids. 
 
3.3 Structure-Activity study of fatty acid accumulation in Dictyostelium 
To examine the structural features of VPA that affect fatty acid regulation we employed a range of 
compounds related to VPA with varying carbon backbone and side chain length, head group and 
saturation.  Radio-label release from 3H-fatty acid-labelled cells following 60 min (0.5 mM) treatment 
was measured (Fig.  5). The compounds tested showed a range of inhibitory activity, from stronger than 
VPA to no change from control. Compounds showing high inhibitory activity were carboxylic acids, 
branched at the second carbon, with the strongest compound containing an isopropyl group.  Branched 
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compounds were generally stronger than corresponding straight chains, with a preference for longer 
side chains (propyl groups showing stronger inhibition than methyl side chains).  
 
3.4 Correlating Dictyostelium fatty acid effects and steatosis 
Since our data suggests a spectrum of fatty acid-regulating activities for the VPA-related compounds 
tested, we then examined the effects of a set of these compounds (showing a wide range of activities) 
on lipid droplet accumulation in human hepatocytes (Huh7 cells). In these experiments, Huh7 cells were 
exposed to VPA or these related compounds for 24 hours prior to staining of lipid droplets and image 
recording (Fig. 6). Compounds showing little attenuation of fatty acid release in Dictyostelium did not 
produce lipid droplets in hepatocytes  (Fig. 6 a, c, e and f), and compounds showing VPA-like inhibitory 
effect on fatty acid release in Dictyostelium had a VPA-like effect on lipid droplet formation in the 
human cells (Fig. 6 b, d, and g). Finally compounds showing a stronger attenuation of fatty acid release 
Dictyostelium compared to VPA also showed enhanced lipid droplet formation in hepatocytes (Fig. 6h 
and i).  
 
3.5 Distinguishing fatty acid, inositol depletion and teratogenic effects 
VPA and related compounds have been widely shown to cause the potentially therapeutic effect of 
inositol depletion, and the side effect of teratogenicity (Terbach and Williams 2009). We thus compared 
activities for compounds of known efficacy in inositol depletion, as previously shown in both 
Dictyostelium InsP3 depletion and mammalian dorsal root ganglia (DRG) neuronal explant experiments, 
and in teratogenicity (Table 1) with effects shown here on fatty acid regulation (in Dictyostelium) and 
lipid droplet formation in huh7 cells.  No relationship was found between inositol depletion efficacy and 
regulation of fatty acids. For example, 2-methyl-2-pentenoic acid was shown to reduce inositol 
trisphosphate (InsP3) in Dictyostelium and to elicit an inositol-dependent increase in growth cone size in 
primary rat dorsal root ganglia (Eickholt et al. 2005)and we show here that it did not affect fatty acid 
regulation in Dictyostelium. In contrast, 2-ethyl-4-methylpentanoic acid had a strong (VPA-like) effect on 
release from fatty acid-labelled cells and was strongly effective in inositol depletion in both 
Dictyostelium and DRG experiments. Similarly, in regards to teratogenicity (Table 1), no correlation was 
shown for compounds when comparing lipid regulation and teratogenic activities (Eickholt et al. 
2005;Riebeling et al. 2011).  
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4. Discussion 
Lipid droplet formation in the liver, steatosis, has been associated with hepatotoxicity (Stephens and 
Levy 1992), and is commonly associated with VPA treatment, although the mechanism giving rise to this 
effect remains unclear (Lagace et al. 2005). Understanding the molecular mechanism for this effect has 
been difficult since VPA gives rise to numerous molecular effects, many of which have not yet been full 
elucidated nor have the effects and pathways been correlated (Terbach and Williams 2009).  To unravel 
the multiple biochemical effects of VPA, we have developed a simple biomedical model, Dictyostelium 
(Adley et al. 2005;Boeckeler et al. 2006;chang et al. 2011;Eickholt et al. 2005;Ludtmann et al. 
2011;Terbach et al. 2011;Williams et al. 2002;Xu et al. 2007). Subsequent to indentifying molecular 
effects of VPA in Dictyostelium, we have then applied this knowledge to mammalian systems to validate 
the model.  Here we investigate the effect of VPA in lipid accumulation and correlate effects shown in 
Dictyostelium to human liver cells.  In this process we have identified a rapid method for examining lipid 
accumulation using Dictyostelium and successfully translated results from this model to a mammalian 
cell line to identify VPA-related compounds exhibiting reduced lipid accumulation.  We also show this 
effect is likely to be unrelated to other VPA-mediated effects of teratogenicity and inositol depletion. 
The identification of analogues with reduced hepatotoxic potential is, therefore, of particular 
importance in the development of novel therapeutics. 
 
VPA increases the accumulation of lipids in Dictyostelium as observed using both fluorescent labelled 
and radio-labelled fatty acids (Figs. 1 and 2).  In the radio-labelled uptake studies, we employed both a 
polyunsaturated fatty acid, AA, and a saturated fatty acid, PaA; both the fatty acids showed enhanced 
accumulation and a decreased release of radio-labelled product over time.  PaA is a naturally occurring 
fatty acid in Dictyostelium and although AA is not normally found in the model, it is both incorporated 
into Dictyostelium phospholipids (Weeks 1976) and triggers the complex cellular and biochemical 
processes involved in Dictyostelium cell movement (Schaloske et al. 2007).  The conserved nature of this 
VPA-induced lipid accumulation, observed with both polyunsaturated and saturated fatty acids, suggests 
a generalised molecular mechanism for VPA in the accumulation of fatty acids within Dictyostelium cells.   
 
The increased accumulation of fatty acids caused by VPA is independent of phospholipid species since 
the distribution of radio-labelled fatty acids into phospholipid classes did not change with treatment 
(Fig. 3). The common trend for an increased fatty acid uptake and incorporation into phospholipids 
between Dictyostelium and human hepatocytes suggests a relevance of this simple model. VPA also 
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caused an increased accumulation of non-polar lipids in both systems (Fig. 2 and 3), consistent with an 
increase in lipid droplet formation since non-polar/neutral lipids typically consist of di- and triacyl-
glycerol species and are stored in these droplets (Kalantari et al. 2010).  These results therefore suggest 
that Dictyostelium may provide a suitable model for liver fatty acid uptake and steatosis research, and 
will enable a combined genetic and biochemical approach to be used in the future to better understand 
this effect. 
 
Although we have shown a linked VPA-induced effect of increased fatty acid uptake and reduced 
release, the use of a cell biology system for this discovery (rather than purified enzymes in biochemical 
approaches) makes identifying the cause of these two effects difficult. However, we note that increased 
lipid droplet formation occurs in presence of only trace quantities of (C1-BODIPY-C12) lipid label – a 
quantity of which is too small to give rise to the substantial increase in lipid droplets upon VPA 
treatment, thus suggesting a VPA-dependent regulation of existing cellular lipids to increase droplet size 
(rather than increased uptake) (Fig. 1). This observation would support a role for VPA and related 
structures (identified in Fig. 5, 6 and Table 1) in regulating cellular fatty acids giving rise to increased 
incorporation into lipid droplets and reduced release. 
 
To investigate the mechanism of VPA-induced fatty acid accumulation in Dictyostelium, we employed a 
range of pharmacological inhibitors of fatty acid turnover enzymes to attempt to phenocopy the effect 
of VPA.  Since PLA2-catalyses the release of fatty acids and has previously been suggested to regulate 
PLA2–dependent signalling (Chang et al. 2001), we employed a cocktail of PLA2 pharmacological 
inhibitors in our cell-based lipid accumulation assay. The effect of PLA2 inhibition was to reduce fatty 
acid accumulation (Fig. 4B).  Similarly, inhibition of DAG acyltransferase also resulted in decreased fatty 
acid accumulation.  These results are consistent with both inhibitors reducing the availability of 
unesterified positions on the glycerol of phospholipids, thus reducing the incorporation of new fatty acid 
into these lipids.  However, since the effect of -oxidation inhibition was to reproduce fatty acid 
accumulation in Dictyostelium, our data is consistent with a role for VPA-induced block in -oxidation 
causing steatosis, although this mechanism is unlikely to be due to inhibition of long-chain acyl-CoA 
dehydrogenases since effects are additive for each drug. 
 
To define the structural prerequisites for VPA-related compounds in inhibiting fatty acid release in 
Dictyostelium, we carried out a SARs study. This study identified a range of activities from no inhibition 
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to more active than VPA. Although no clear structural constrains are evident from the compounds 
tested here, this study provided a rapid means for testing potential lipid regulatory effects of VPA 
congeners. Using a selection of inactive and highly active compounds identified in the Dictyostelium 
study, similar efficacies were shown in lipid droplet formation in Human hepatocytes (Huh7 cells).   In 
addition, this study enabled the investigation of a potential overlap between this effect and VPA-
induced inositol signalling inhibition and teratogenicity. Here, we compared activity of a range of VPA-
related compounds (Fig. 5) with varying backbone length, different and side chain length and position, 
and for inhibitory activity in fatty acid release, teratogenicity (HDAC inhibition) and inositol depletion 
strengths (Eickholt et al. 2005;Eikel et al. 2006;Shimshoni et al. 2007).  The structural characteristics of 
compounds inhibiting fatty acid release are different to those of teratogenicity, since a range of 
compounds showing enhanced or reduce inositol depletion or teratogenic activity do not shown 
corresponding activity for this fatty acid-related effect (Table 1). Fatty acid regulation, teratogenicity and 
inositol depletion may therefore provide three independent mechanisms of action for VPA in 
Dictyostelium.  This study also provides the first description of VPA-related compounds for the 
regulation of fatty acid accumulation. 
 
Continued research to understand the molecular mechanisms of lipid droplet formation and subsequent 
steatosis may help in the development of novel therapeutic treatments with improved risk:benefit 
ratios.  It should be noted that it is not currently clear if the observed lipid droplet accumulation has only 
detrimental consequences. For example, an increase in free AA has been shown in the brain following 
seizures Basselin et al. 2003; Bazan et al. 2002; Rintala et al. 1999), and a reduction in AA signalling has 
also been observed in both epilepsy and bipolar disorder patient populations following treatment 
(Basselin et al. 2003;Bazinet et al. 2005). Our identification of a simple model system to study these 
effects and the identification of a structural specificity for an effect on fatty acid regulation may provide 
a potential mechanism for selection of novel therapeutics that lacks the current side effects of weight 
gain during VPA treatment (Masuccio et al. 2010;Verrotti et al. 2011b;Wirrell 2003).  
 
In conclusion, we describe the analysis of a VPA-induced change in fatty acid uptake and release in the 
simple model Dictyostelium.  We demonstrate an acute VPA-induced incorporation of fatty acids into 
complex glycerolipids, consistent with the observed lipid droplet accumulation in hepatocytes.  This 
effect occurs with both a poly-unsaturated and a saturated fatty acid through incorporation into 
different phospholipids and non-polar lipids in Dictyostelium (and for AA-labelling in hepatocytes) and 
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appears, at least in part, due to a block in -oxidation caused by VPA.  We have also identified a range of 
novel compounds with varying strength of inhibitory effects on fatty acid release, identifying a range of 
compounds with either enhanced or reduced activity (compared to VPA) and validated this using a 
human hepatocyte cell line.  Finally, this data suggests that the VPA-induced fatty acid regulation is 
independent of teratogenic or inositol depletion efficacy.  
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Figure Legends 
Figure 1 
VPA induces lipid droplet 
accumulation of fluorescent C1-
BODIPY-C12 in Dictyostelium.  (a) Cells 
were incubated for 30 minutes with 
the fluorescent fatty acid C1-BODIPY-
C12 in the absence (i, iii, v) or presence 
(ii, iv, vi) of VPA (0.5mM).  Analysis of 
lipid droplets by fluorescent imaging in 
(i) untreated and (ii) VPA-treated cells 
shows increased droplet size and 
intensity. Fluorescent visualisation of 
cell populations for (iii) untreated and 
(iv) VPA-treated samples, compared to 
corresponding transmission images (v 
and vi respectively), also shows this 
increase. (b) Quantification of 
individual droplet intensity and 
average diameter compared to 
control, as measured by ImagePro 
software (t test, *** p<0.001, * 
p<0.05).  Cell images contained 
approximately 12500 pixels per cell.  
Scale bar for i and ii (shown in (ii)) = 10 
m; for iii – vi (shown in (iii)) = 50 m. 
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Figure 2 
VPA induces changes 
in fatty acid uptake 
and release in a 
time- and 
concentration-
dependent manner.  
(a and b) 
Dictyostelium wild 
type cells (Ax2) were 
used to monitor the 
uptake of 3H-
arachidonic acid (a) 
or 3H-palmitic acid 
(b) into cells in the 
absence () or 
presence ()  of VPA 
(0.5 mM) and 
quantified by 
scintillation counting. This effect was also monitored following TLC separation of the cellular lipids for (c) 
3H-arachidonic acid and (d) 3H-palmitic acid. Total lipid loading is shown following copper sulphate 
(CuSO4) staining. Cells were pre-incubated with (e) 
3H-arachidonic acid or (f) 3H-palmitic acid for 1 hour 
before removing excess label and scintillation quantification of release of 3H into external buffer in the 
absence () or presence () of VPA (0.5 mM). Results from scintillation assays (a, b, e and f) are 
expressed as the percentage of 3H in cpm obtained from control samples at 60 minutes.  Insets show 
dose response curves at 30 minutes, expressed as a percentage of 3H uptake/release in the absence of 
VPA. Statistics and dose response curves were calculated using Graphpad Prism™ software with linear 
regression for line fitting based upon 0-30 min data.  All data are replicates of at least 3 independent 
experiments and show means ± SEM. PC, phosphatidylcholine; PE, phosphatidylethanolamine. 
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Figure 3 
2D TLC analysis of radio-labelled lipids in Dictyostelium and in Human hepatocyte (Huh7) cells indicates 
general accumulation into phospholipids and neutral lipids following VPA treatment.  In Dictyostelium, 
radio-labelling cells with 3H-arachidonic acid under (a) control conditions or (b) during exposure to VPA 
(60 min, 1.0 mM), followed by lipid extraction, 2D separation and visualisation by phosphorimage 
analysis enabled the identification of phospholipid species accumulating the radio-labelled fatty acid.  
Individual phospholipid species were then quantified by scintillation counting following (c) 3H-
arachidonic acid (d) or 3H-palmitic acid labelling in the presence or absence of VPA. (e) Quantification of 
phospholipid species labelling in Huh7 cells, incubated in the presence of 3H-arachidonic acid with or 
without VPA for 1 hour prior to lipid harvesting.* p<0.05, ** p<0.01. PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; PG phosphatidylglycerol; 
NL, NL= non-polar (neutral) lipids. 
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Figure 4 
Pharmacological 
evaluation of lipid 
accumulation.  (a) 
Schematic representation 
of the pharmacological 
approach taken to 
investigate VPA-mediated 
fatty acid regulation. 
Phoshpholipase A2 (PLA2) 
activity gives rise to the 
release of fatty acids from 
phospholipids  in the 
membrane, whereas DAG 
acyl transferase catalyses 
the interconversion of 
neutral lipids, both effects 
potentially responsible for 
regulating fatty acid levels, and thus may be effected by an inhibition of  oxidation of fatty acids.  (b) 
Dictyostelium were labelled with 3H arachidonic acid in the presence of various drugs: 1mM VPA, 50μM 
xanthohumol (DAG acyl transferase inhibitor), PLA2 inhibitor cocktail (BEL [80 μM], a Ca
2+-independent 
PLA2 inhibitor; MAFP [50 μM], an inhibitor of Ca
2+-dependent and Ca2+-independent cytosolic PLA2; and 
BPB [20 μM], a general phospholipase A2 inhibitor)  or 2-mercaptoacetate (2-MA, 15 mM, an inhibitor of 
long-chain acyl-CoA dehydrogenase).  (c) Uptake of 3H-arachidonic acid over time in the absence (), or 
presence of VPA (0.5 mM; ), 2-MA (15 mM;∆), or combined VPA and 2-MA (▲). Statistical analysis was 
performed by GraphPad Prism software using a Student’s t test, *** p<0.001, ** = p<0.005 and * = 
p<0.05 versus control. 
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Figure 5 
Structural requirements for VPA-related compounds to inhibit fatty acid release in Dictyostelium.  Effects 
of a wide range of VPA-related compounds were tested by measuring 3H release from 3H-AA labelled 
cells.  Compounds are grouped into straight chain analogues, 2-branched, 3-branched, 4-branched, 
unsaturated VPA analogues or other VPA-related compounds. This approach provided a rapid 
mechanism for screening VPA-related compounds for regulating fatty acids in vivo. (TMCA = 2,2,3,3-
tetramethylcyclopropanecarboxylic acid, PIA = 2-isopropyl-pentanoic acid, VPD = valpromide).  Statistical 
analysis was performed using GraphPad Prism software using a one way ANOVA with a Tukey post hoc.  
*** = p<0.001 vs control, ns = not significant versus control, +++ = p<0.001 vs VPA, ns = not significant 
versus VPA. 
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Figure 6 
Lipid droplet accumulation caused by VPA-related compounds in human hepatocytes (imaged) 
correlates with inhibitory activity for fatty acid release in Dictyostelium (Fig 5). (a,c) Lipid droplets, 
visualised as patches of small circular white/pink spots, do not commonly appear in untreated human 
hepatocytes (Huh7 cells), (b,d) but are evident following 24h VPA treatment (arrows).  VPA-related 
compounds showing no inhibitory effect on radio-label release from 3H-arachidonic acid labelled 
Dictyostelium cells did not induce lipid droplet formation in hepatocytes ((e) pentanoic acid and (f) 
TMCA). In contrast, compounds shown to cause a VPA-like effect on Dictyostelium fatty acid release ((g) 
4-methylnonanoic acid) cause a showed similar efficacy in causing increased lipid droplet accumulation. 
Compounds shown to be more strongly active than VPA in Dictyostelium also gave rise to increased lipid 
droplet formation over VPA treatment in hepatocytes ((h) nonanoic acid and (i) 2-propyloctanoic acid).  
White arrows indicate oil red-O stained lipid droplets, size bars represent 200 pixels. 
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compound  FA release  
(% control)  
(Dicty)  
Lipid  
droplets  
(huh7)  
Teratogen-  
icity  
InsP
3
  
 depleting  
(Dicty)  
DRG-inositol  
dependent  
 effect (rat)  
Reference 
VPA (2-propylpentanoic acid)  52±10  3  +++  xxx  YES  Eickholt et al. 2005;Williams et 
al. 2002  
Valpromide (2-propyl pentamide, VPD)  99±11  0  0  x  NO  Eickholt et al. 2005; Shimshoni 
et al. 2007; Eikel et al. 2006  
Pentanoic acid  91±8  1  0  -  -  
 
2-methyl-2-pentenoic acid  88±13  -  0  xx  YES  Eickholt et al. 2005  
2-propyl-4-pentynoic acid  90±8  0  +++  -  -  Eikel et al. 2006  
2-ethyl-4-methylpentanoic acid  36±5  -  0  xx  YES  Eickholt et al. 2005; Riebeling 
et al. 2011  
2-isopropyl pentanoic acid (PIA)  34±4  4  0  xxx  YES  Eyal et al. 2005; Shimshoni et 
al. 2007  
diisopropylacetic acid (DIA)  96±11  0  0  0  YES  Eyal et al. 2005; Shimshoni et 
al. 2007  
R2-pentyl-4-pentynoic acid  69±5  -  +++  0  -  Eickholt et al. 2005; Riebeling 
et al. 2011  
S2-propyl-4-hexynoic acid  94±12  -  +++  xx  YES  Eickholt et al. 2005 
R2-propyl-4-hexynoic acid 92±12  -  +  0  NO  Eickholt et al. 2005; Eikel et al. 
2006  
TMCA 88±11  0  0  x  NO  Shimshoni et al. 2007; Eyal et 
al. 2005 
2-propyloctanoic 45±4  4  +++  -  -  Eikel et al. 2006  
Nonanoic acid 66±13  4  -  -  -  
 
4-methylnonanoic 56±6  4  -  -  -  
 
 
Table 1  
 Comparison of VPA-related compounds activity in the inhibition of Dictyostelium fatty acid (FA) release and the 
formation of human (huh7) liver cell lipid droplet (shown here), teratogenicity, and inositol signalling-based effects 
in Dictyostelium and rat primary dorsal root ganglia (DRG) neurons. Compound activity for inhibition of FA release 
in Dictyostelium is given as a percentage of control (no added compound) activity. Lipid droplet formation in huh7 
cells was rated on an arbitrary scale: (0) no effect; (1) low inhibition; (1) up to 25% inhibition; (2), between 25% and 
VPA-like activity; (3)inhibition similar to that of VPA; (4) inhibition greater than VPA. Teratogenic rating is shown on 
an arbitrary scale, as defined by [6] and [54]: (0) not teratogenic, (+) low teratogenicity, (++) intermediate 
teratogenicity, (+++) VPA-like teratogenicity or higher. Inositol trisphosphate (InsP3)-depletion effects, using 
Dictyostelium as a model, is also shown on an arbitrary scale: (0), no InsP3 depletion effect; (x) low InsP3 reduction; 
(xx) intermediate reduction; (xxx) high reduction similar to VPA. Rat dorsal root ganglia (DRG) inositol-dependent 
increase in growth cone area, as shown previously (Eickholt et al. 2005), was also rated as (YES) or (NO). TMCA = 
2,2,3,3-tetramethylcyclopropanecarboxylic acid. – Not determined. 
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TRANSLATIONAL IMPACT 
 
Clinical issue  
Valproic acid (VPA) is commonly prescribed for epilepsy and bipolar disorder, as well as for migraine prophylaxis. 
However, despite more than 45 years of research, its mechanisms of action are still unclear. Furthermore, 
although VPA has several significant side effects, improved therapies based on its structure but without these side 
effects have yet to be developed. Among side effects are hepatotoxicity and non-alcoholic fatty liver disease (also 
known as hepatic steatosis), suggesting that VPA has adverse effects on lipid metabolism in the liver including the 
formation of lipid droplets in human hepatocytes in vitro. The mechanism of this effect is unclear. The 
development of model systems to investigate VPA-related compounds with reduced hepatotoxic potential will aid 
in the development of safer therapies for indications that are treated with this drug. 
 
Results 
In this paper, the authors use a simple model system, the social amoeba Dictyostelium discoideum, to analyse the 
adverse effects of VPA on fatty acid metabolism, and specifically its role in inducing the formation of intracellular 
lipid droplets. As previously observed in human hepatocytes, they first show that pharmacologically relevant 
amounts of VPA also cause lipid accumulation in Dictyostelium. Following VPA treatment, fatty acids are taken up 
and incorporated into specific phospholipids, with a concurrent reduction in fatty acid release, an effect caused at 
least in part by inhibiting β-oxidation of fatty acids. The authors then use structure-activity analysis to screen a 
panel of VPA-related compounds for this inhibitory effect, and show that the magnitude of inhibition depends on 
chemical structural features of the compounds. Testing a selection of these compounds with a range of activities 
in human hepatocytes indicates a high correlation: compounds that inhibit fatty acid release in Dictyostelium 
cause lipid droplet formation human hepatocytes, whereas compounds with minimal effect on fatty acid release 
in Dictyostelium do not induce lipid droplets formation in hepatocytes.  
 
Implications and future directions  
This study suggests that Dictyostelium can be used as a non-animal model for analysing the adverse effects of VPA 
and related compounds on lipid droplet formation. It also identifies novel compounds (and a system to identify 
more) that have mechanisms similar to VPA but that are unlikely to cause effects on lipid droplet formation in 
hepatocytes, and should therefore help to identify safer treatments for epilepsy, bipolar disorder and migraine. 
 
 
